AHCO stock forecast, quote, news & analysis
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services... Show more
Why AdaptHealth Corp. (AHCO) Stock Is Down -34.7% in the Last 30 Days
Key Takeaways
- AdaptHealth Corp. (AHCO) shares plummeted approximately 34.7% over the last 30 days, with nearly all losses concentrated in a single session following the company's Q2 2026 earnings release on August 4, 2026.
- The company reported a staggering earnings miss: a GAAP loss of $0.99 per share versus analyst expectations for a $0.15 profit, alongside revenue of $740.3 million that fell well short of the $848.9 million consensus.
- Full-year 2026 guidance was slashed dramatically, with revenue now forecast at $2.85 billion to $2.89 billion — roughly 17.7% below Wall Street's prior consensus — and adjusted EBITDA cut to $490 million to $520 million.
- A $144.2 million non-cash goodwill impairment, escalating costs tied to a West Coast capitated contract, and an unexpected manufacturer price increase were the primary culprits behind the profit collapse.
- The company announced a strategic pivot: the sale of its Diabetes Health business for $235 million in cash, an e-commerce joint venture, and a sharpened focus on its core Sleep Health and Respiratory Health segments.
AdaptHealth Corp. (AHCO) Company Overview and Market Position
AdaptHealth Corp. is a national leader in patient-centered, healthcare-at-home solutions, providing home medical equipment, medical supplies, and related services to patients with chronic conditions such as sleep apnea, COPD, and respiratory disorders. Operating through a network of approximately 680 locations across all 50 states, the company generates revenue across three primary segments: Sleep Health, Respiratory Health, and Wellness at Home. Sleep Health is the largest contributor, representing roughly 52% of total continuing-operations revenue. The company has historically grown through an aggressive acquisition strategy — completing more than 150 deals — and is now undertaking a significant portfolio rationalization to concentrate on its highest-margin, highest-growth core businesses. Investors track AHCO closely for its exposure to the growing home-healthcare trend and its evolving capitated-contract model with major payers.
AdaptHealth Corp. (AHCO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AHCO shares declined approximately 34.7%, tumbling from a closing price of $10.27 on July 6, 2026, to $6.70 on August 4. The selloff was overwhelmingly concentrated on August 4, when the stock collapsed roughly 38% in a single trading session after the company released its second-quarter earnings report and sharply reduced full-year guidance. Trading volume surged to nearly 12 million shares — roughly eight times the daily average of 1.5 million — underscoring the intensity of institutional repositioning.
The quarterly picture is equally stark. Through the first two months of the quarter, AHCO traded in a relatively narrow band between $10 and $11, with the stock actually up approximately 12% year-to-date heading into the August 4 report. After the earnings-driven capitulation, the shares now sit near the bottom of their 52-week range of $6.14 to $13.43, representing a roughly 51% drawdown from the April 2026 high.
What Drove AHCO Stock Price in the Last 30 Days
The overwhelming catalyst for AHCO's 30-day decline was the Q2 2026 earnings release on August 4, which triggered one of the most severe single-day selloffs in the company's history. AdaptHealth reported a GAAP loss of $0.99 per share — a miss of $1.14 versus the consensus estimate of a $0.15 profit. Revenue of $740.3 million missed expectations by over $108 million despite growing 12.7% year-over-year on a continuing-operations basis and posting 15.9% organic growth.
The deeper alarm for investors came from forward guidance. Management cut its full-year 2026 adjusted EBITDA outlook to $490 million–$520 million, down from a prior range of $680 million–$730 million, and reduced the revenue forecast to $2.85 billion–$2.89 billion from approximately $3.49 billion. Three major headwinds were cited: a $55 million impact from escalating costs and higher-than-expected patient volumes on a West Coast capitated contract with a large national integrated delivery network; a $30 million hit from an unexpected manufacturer price increase after a key supplier terminated its contract effective June 30; and approximately $100 million in EBITDA impact from the reclassification of the Diabetes Health business as discontinued operations, including $60 million of stranded corporate overhead.
A $144.2 million non-cash goodwill impairment charge, negative free cash flow of $20.9 million in the quarter, and elevated capital expenditures of $166.2 million further rattled confidence. The news also prompted law firm Holzer & Holzer to announce an investigation into whether the company complied with federal securities laws.
What Drove AHCO Stock Performance Over the Last Quarter
Before the August 4 earnings shock, AHCO shares had been range-bound with a slight downward bias, reflecting lingering investor caution from the prior quarter's mixed results. In March 2026, the stock dropped 16.4% after Q4 2025 results revealed a GAAP loss of $0.76 per share and an operating margin that contracted to negative 8.7%. Despite those headwinds, shares recovered into the $10–$11 range through June and July, buoyed by optimism around expanding capitated contracts — including a new agreement with Humana OneHome covering 478,000 members across South Florida and Texas — and the rollout of an AI-powered mask-fitting tool that achieved a 92% conversion rate.
The quarterly narrative ultimately shifted from cautious optimism to a full-scale confidence reset. The combination of margin compression, guidance cuts, a cybersecurity incident requiring settlement expenses, a workforce restructuring generating $19 million in annualized savings, and the realization that the West Coast capitated contract would not reach its 20% margin target until 2027 at the earliest overwhelmed any positive signals from organic growth acceleration. The stock's quarterly decline mirrors a broader market reassessment of the company's ability to translate volume growth into sustainable profitability.
Trending AI Robots
In a market environment where individual stock analysis can be both time-consuming and emotionally driven, algorithmic trading tools have gained traction among investors seeking data-driven decision-making. Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing AI-powered trading bots, each executing distinct strategies across thousands of tickers and varying timeframes. These bots are designed to analyze market patterns, technical indicators, and fundamental data without human bias, and only the strongest performers make it into the Trending section. Whether focusing on short-term swing trades or longer-duration positions, the bots' strategies and historical performance metrics are presented transparently, allowing users to evaluate approaches that align with their own objectives. Exploring the Trending AI Robots page can offer a practical entry point for those curious about how artificial intelligence is reshaping modern trading.
AHCO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several critical factors will determine whether AHCO shares can stabilize and recover. First, investors will closely monitor the Q3 2026 earnings release for evidence that the West Coast capitated contract is improving — management guided to modest sequential improvement of roughly $1 million per quarter — and whether the manufacturer pricing dispute reaches a resolution. Second, the successful closing of the $235 million Diabetes Health sale and the application of proceeds toward debt reduction will be pivotal; the company carries approximately $1.94 billion in long-term debt against just $43.3 million in unrestricted cash, with leverage at 3.06 times adjusted EBITDA. Third, the trajectory of free cash flow — guided to $80 million–$120 million for the full year but requiring a sharp second-half reversal — will test management's credibility. Finally, any updates on the e-commerce joint venture, further capitated contract wins, and adoption of the AI-powered mask-fitting tool could provide positive counterpoints to the prevailing bearish narrative. The Holzer & Holzer investigation, while not yet resulting in formal charges, represents an additional overhang that investors should not overlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AHCO in upward trend: price may ascend as a result of having broken its lower Bollinger Band on August 04, 2026
AHCO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 43 cases where AHCO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where AHCO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AHCO advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AHCO as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AHCO turned negative on August 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
AHCO moved below its 50-day moving average on August 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AHCO crossed bearishly below the 50-day moving average on August 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for AHCO moved below the 200-day moving average on July 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AHCO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for AHCO entered a downward trend on August 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.547) is normal, around the industry mean (11.125). P/E Ratio (16.491) is within average values for comparable stocks, (71.075). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.012). AHCO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (0.229) is also within normal values, averaging (34.649).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AHCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AHCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical products for both rental and sale
Industry MedicalNursingServices